医学
颈淋巴结清扫术
外科
癌症
回顾性队列研究
放射治疗
阶段(地层学)
内科学
古生物学
生物
作者
Stefano Zorzi,Giacomo Pietrobon,Chiara Mossinelli,Francesco Bandi,Francesco Chu,Marta Tagliabue,Rita De Berardinis,Jacopo Zocchi,Daniela Alterio,Maria Cossu Rocca,Francesca Ruju,Mohssen Ansarin
标识
DOI:10.1016/j.amjoto.2023.104113
摘要
The neck management in early-stage cN0 supraglottic cancer represents an argument of debate. The aim of our study is to evaluate the oncological and functional outcomes in patients with early-stage cN0 supraglottic carcinoma treated with a wait-and-see policy for the neck. Retrospective monocentric cohort study in a referral cancer care center. We collected a consecutive sample of patients from 2000 to 2020 with Squamous Cell Carcinoma of the supraglottis without clinical evidence of nodal metastases (cN0), surgically treated with Transoral Surgery (Laser or Robotic) without neck dissection. From 316 supraglottic cancer we finally selected 66 eligible participants that met all inclusion criteria. Sixty-six patients (M 75.8 % vs F 24.2 %), median age 65.8 years (IQR 60.9, 70.5). The most common subsite was the epiglottis (62.1 %). Tumor stage distribution was as follows: 35 % cT1, 53 % cT2, 15.2 % cT3. Neither deaths nor major treatment-related complications were reported after surgery. The median follow-up was 62 months. For oncological outcomes, we evaluated 56 patients (10 excluded for adjuvant radiotherapy): 5-year overall survival rate 87 % (CI 95 %: 73.1–94), disease- specific survival rate 95.3 % (CI 95 %: 82–98.8) and neck recurrence-free survival rate 87 % (CI 95 %: 73.1–94). Six patients developed neck recurrence, with a median time of 13 months. Supraglottic carcinoma has been historically associated to a considerable risk of occult metastasis. However, in early-stage cases data are still inconclusive. Our results suggest that in such patients a wait-and-see policy does not impact negatively on survival outcomes, while granting the reduced morbidity associated to a minimally invasive surgical approach.
科研通智能强力驱动
Strongly Powered by AbleSci AI